The estimated Net Worth of Jr. Mark L. Lupher, is at least $914 millier dollars as of 7 February 2024. Jr Lupher owns over 130,000 units of Adverum Biotechnologies Inc stock worth over $913,900 and over the last 6 years Jr sold ADVM stock worth over $0.
Jr has made over 1 trades of the Adverum Biotechnologies Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently Jr bought 130,000 units of ADVM stock worth $175,500 on 7 February 2024.
The largest trade Jr's ever made was buying 130,000 units of Adverum Biotechnologies Inc stock on 7 February 2024 worth over $175,500. On average, Jr trades about 14,444 units every 0 days since 2019. As of 7 February 2024 Jr still owns at least 130,000 units of Adverum Biotechnologies Inc stock.
You can see the complete history of Jr Lupher stock trades at the bottom of the page.
Jr's mailing address filed with the SEC is C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY, CA, 94063.
Over the last 9 years, insiders at Adverum Biotechnologies Inc have traded over $1,591,374 worth of Adverum Biotechnologies Inc stock and bought 912,973 units worth $4,153,055 . The most active insiders traders include Patrick Machado, Braden Michael Leonard et Thomas Woiwode. On average, Adverum Biotechnologies Inc executives and independent directors trade stock every 40 days with the average trade being worth of $200,186. The most recent stock trade was executed by Braden Michael Leonard on 30 July 2024, trading 85,800 units of ADVM stock currently worth $613,470.
adverum (nasdaq: advm) is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. we are advancing the development of a robust pipeline of gene therapies that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (a1at) deficiency and hereditary angioedema (hae) as well as wet age-related macular degeneration (wamd). leveraging our next-generation adeno-associated virus (aav)-based directed evolution platform, we generate gene therapies designed to provide durable efficacy by inducing sustained expression of a therapeutic protein.
Adverum Biotechnologies Inc executives and other stock owners filed with the SEC include: